Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial - Takeaways - MDSpire

Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial

  • By

  • Ghazaleh Tabatabai

  • Isabel Ramirez

  • Beatrix Welte

  • Paula Bombach

  • Hannes Becker

  • Denise Bernhardt

  • Regine Mayer-Steinacker

  • Friedegund Meier

  • Nicolas Neidert

  • Roland Roelz

  • Iris Mildenberger

  • Lukas Bunse

  • Michael Platten

  • Ulrich Herrlinger

  • Uwe M. Martens

  • Ulrike Ernemann

  • Manuela Neumann

  • Marcos Tatagiba

  • Lina Maria Serna-Higuita

  • Peter Martus

  • Mirjam Renovanz

  • June 4, 2026

  • 0 min

Share

  • 1

    Leptomeningeal disease (LMD) occurs in 5-10% of solid tumor patients, primarily from lung, breast cancer, or melanoma.

  • 2

    LMD is associated with a poor prognosis, with median overall survival ranging from 4 to 8 weeks post-diagnosis.

  • 3

    The IT-PD1/NOA-26 trial evaluates intrathecal nivolumab in LMD patients, focusing on safety and maximum tolerable dose.

  • 4

    Eligible participants had a Karnofsky performance score > 50% and confirmed LMD diagnosis via CSF cytology or MRI.

  • 5

    The trial included 30 participants, with 24 meeting all inclusion and exclusion criteria by the data cutoff date.

Original Source(s)

Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial

  • by Ghazaleh Tabatabai, Isabel Ramirez, Beatrix Welte, Paula Bombach, Hannes Becker, Denise Bernhardt, Regine Mayer-Steinacker, Friedegund Meier, Nicolas Neidert, Roland Roelz, Iris Mildenberger, Lukas Bunse, Michael Platten, Ulrich Herrlinger, Uwe M. Martens, Ulrike Ernemann, Manuela Neumann, Marcos Tatagiba, Lina Maria Serna-Higuita, Peter Martus, Mirjam Renovanz

  • June 4, 2026

Related Content

Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis

Comprehensive Cancer Care for the Doral Community

Baptist Health Cancer Care is now serving patients in Doral with a comprehensive, community-based approach to oncology care designed to make treatment more convenient and accessible for both patients and referring physicians.

  • by

  • June 2, 2026

  • 2 min
Prognostic significance and model evaluation of the modified advanced lung cancer inflammation index in locally advanced resectable gastric cancer patients with neoadjuvant chemotherapy